231 S. Whisman Rd
3 articles with SanBio
The SanBio Group has updated part of its March 13, 2018 release “Update on Development Progress of Regenerative Cell Medicine SB623”.
SanBio Reaches Agreement on Manufacture of Regenerative Medicine Product SB623 with Hitachi Chemical
SanBio Group and Hitachi Chemical Co., Ltd. jointly announced that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC, they will manufacture SB623, a proprietary regenerative medicine product under development by SanBio.
SanBio and Teijin Limited jointly announced today that they would terminate the exclusive licensing agreement signed in 2009 regarding the development and marketing of SB623 for stroke treatment in Japan.